These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 26066997)

  • 1. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
    Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
    Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
    Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
    Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards replacement of animal tests with in vitro assays: a gene expression biomarker predicts in vitro and in vivo estrogen receptor activity.
    Corton JC; Liu J; Kleinstreuer N; Gwinn MR; Ryan N
    Chem Biol Interact; 2022 Aug; 363():109995. PubMed ID: 35697134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On selecting a minimal set of in vitro assays to reliably determine estrogen agonist activity.
    Judson RS; Houck KA; Watt ED; Thomas RS
    Regul Toxicol Pharmacol; 2017 Dec; 91():39-49. PubMed ID: 28993267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
    Bishop PL; Willett CE
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches.
    Zhang L; Sedykh A; Tripathi A; Zhu H; Afantitis A; Mouchlis VD; Melagraki G; Rusyn I; Tropsha A
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):67-76. PubMed ID: 23707773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development, validation and integration of in silico models to identify androgen active chemicals.
    Manganelli S; Roncaglioni A; Mansouri K; Judson RS; Benfenati E; Manganaro A; Ruiz P
    Chemosphere; 2019 Apr; 220():204-215. PubMed ID: 30584954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
    Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
    Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemistry domain of applicability evaluation against existing estrogen receptor high-throughput assay-based activity models.
    Nelms MD; Antonijevic T; Ring C; Harris DL; Bever RJ; Lynn SG; Williams D; Chappell G; Boyles R; Borghoff S; Edwards SW; Markey K
    Front Toxicol; 2024; 6():1346767. PubMed ID: 38694816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational analysis of the ToxCast estrogen receptor agonist assays to predict vitellogenin induction by chemicals in male fish.
    Dreier DA; Denslow ND; Martyniuk CJ
    Environ Toxicol Pharmacol; 2017 Jul; 53():177-183. PubMed ID: 28645054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening tools facilitate calculation of a combined exposure-bioactivity index for chemicals with endocrine activity.
    Wegner SH; Pinto CL; Ring CL; Wambaugh JF
    Environ Int; 2020 Apr; 137():105470. PubMed ID: 32050122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Estrogenic Bioactivity of Environmental Chemical Metabolites.
    Pinto CL; Mansouri K; Judson R; Browne P
    Chem Res Toxicol; 2016 Sep; 29(9):1410-27. PubMed ID: 27509301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space.
    Shah F; Greene N
    Chem Res Toxicol; 2014 Jan; 27(1):86-98. PubMed ID: 24328225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of candidate reference chemicals for in vitro steroidogenesis assays.
    Pinto CL; Markey K; Dix D; Browne P
    Toxicol In Vitro; 2018 Mar; 47():103-119. PubMed ID: 29146384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binary classification of a large collection of environmental chemicals from estrogen receptor assays by quantitative structure-activity relationship and machine learning methods.
    Zang Q; Rotroff DM; Judson RS
    J Chem Inf Model; 2013 Dec; 53(12):3244-61. PubMed ID: 24279462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor.
    Judson RS; Magpantay FM; Chickarmane V; Haskell C; Tania N; Taylor J; Xia M; Huang R; Rotroff DM; Filer DL; Houck KA; Martin MT; Sipes N; Richard AM; Mansouri K; Setzer RW; Knudsen TB; Crofton KM; Thomas RS
    Toxicol Sci; 2015 Nov; 148(1):137-54. PubMed ID: 26272952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay.
    Beames T; Moreau M; Roberts LA; Mansouri K; Haider S; Smeltz M; Nicolas CI; Doheny D; Phillips MB; Yoon M; Becker RA; McMullen PD; Andersen ME; Clewell RA; Hartman JK
    Toxicol Appl Pharmacol; 2020 Jan; 387():114774. PubMed ID: 31783037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
    Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
    Marty MS; O'Connor JC
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.